November 12, 2021
Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting
October 26, 2021
Xilio Therapeutics Announces Closing of Initial Public Offering
October 21, 2021
Xilio Therapeutics Announces Pricing of Initial Public Offering
October 18, 2021
Xilio Therapeutics Announces FDA Clearance of Investigational New Drug Application for XTX202 for the Treatment of Solid Tumors
October 12, 2021
Xilio Therapeutics Appoints Timothy D. Hunt as Chief Culture and Corporate Affairs Officer
September 16, 2021
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX101 for the Treatment of Patients with Solid Tumors
August 17, 2021
Xilio Therapeutics Appoints Sara Bonstein to Its Board of Directors
June 17, 2021
Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors
May 25, 2021
Xilio Therapeutics Announces Clinical Trial Collaboration With Merck on Anti-CTLA-4 Monoclonal Antibody Program
May 20, 2021
Xilio Therapeutics to Present Preclinical Data Highlighting Anti-Tumor Activity and Tolerability of XTX202 at the 2021 ASCO Annual Meeting
Displaying 1 - 10 of 15